Boston Advisors LLC lessened its holdings in Merck & Company, Inc. (NYSE:MRK) by 3.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 369,965 shares of the company’s stock after selling 12,080 shares during the period. Boston Advisors LLC’s holdings in Merck & were worth $23,711,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also bought and sold shares of the company. Cascade Investment Advisors Inc. raised its stake in Merck & by 15.5% in the 2nd quarter. Cascade Investment Advisors Inc. now owns 1,727 shares of the company’s stock valued at $111,000 after acquiring an additional 232 shares during the period. Vigilant Capital Management LLC raised its stake in Merck & by 16.7% in the 1st quarter. Vigilant Capital Management LLC now owns 1,746 shares of the company’s stock valued at $111,000 after acquiring an additional 250 shares during the period. Harbour Capital Advisors LLC bought a new stake in Merck & in the 1st quarter valued at $127,000. Gradient Investments LLC raised its stake in Merck & by 41.3% in the 1st quarter. Gradient Investments LLC now owns 2,306 shares of the company’s stock valued at $147,000 after acquiring an additional 674 shares during the period. Finally, Pinnacle Bank bought a new stake in Merck & in the 1st quarter valued at $152,000. Institutional investors and hedge funds own 73.02% of the company’s stock.
Merck & Company, Inc. (MRK) traded down 0.41% during mid-day trading on Friday, reaching $65.85. The company had a trading volume of 6,961,883 shares. The stock has a 50 day moving average price of $63.34 and a 200-day moving average price of $63.72. Merck & Company, Inc. has a 12-month low of $58.29 and a 12-month high of $66.80. The stock has a market capitalization of $179.60 billion, a P/E ratio of 35.65 and a beta of 0.81.
Merck & (NYSE:MRK) last posted its earnings results on Friday, July 28th. The company reported $1.01 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.87 by $0.14. Merck & had a return on equity of 26.02% and a net margin of 17.14%. The business had revenue of $9.93 billion during the quarter, compared to analysts’ expectations of $9.75 billion. During the same period in the previous year, the business earned $0.93 earnings per share. The firm’s revenue was up .9% on a year-over-year basis. Equities analysts anticipate that Merck & Company, Inc. will post $3.87 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 6th. Stockholders of record on Friday, September 15th will be issued a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 2.84%. The ex-dividend date of this dividend is Thursday, September 14th. Merck &’s payout ratio is currently 76.11%.
A number of equities research analysts recently weighed in on the company. BMO Capital Markets restated a “buy” rating and issued a $74.00 price target on shares of Merck & in a research note on Tuesday, June 27th. BidaskClub upgraded Merck & from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. Zacks Investment Research raised Merck & from a “hold” rating to a “buy” rating and set a $73.00 price objective on the stock in a report on Friday, May 26th. Credit Suisse Group set a $72.00 price objective on Merck & and gave the company a “buy” rating in a report on Tuesday, June 6th. Finally, Jefferies Group LLC reaffirmed a “sell” rating and issued a $51.00 price objective on shares of Merck & in a report on Wednesday, May 24th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have assigned a buy rating to the company. Merck & has an average rating of “Hold” and a consensus price target of $70.00.
TRADEMARK VIOLATION WARNING: This news story was originally posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.chaffeybreeze.com/2017/09/15/merck-company-inc-mrk-shares-sold-by-boston-advisors-llc.html.
About Merck &
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.